Further studies on the xylazine-yohimbine interaction.
A study of the Yohimbine-blocking action upon Xylazine-ability to inhibit the abdominal contortions elicited by an intraperitoneal injection of Acetic Acid (60 mg/kg) was carried out. Xylazine (0.75 mg/kg - subcutaneously) inhibited 44% of the abdominal contortions. Such an inhibition activity was reduced to a 19% level after a previous Yohimbine treatment (1 mg/kg - intramuscularly - 30 min before). The results suggested there is a 2.9 times reduction of Xylazine affinity for CNS alpha 2 receptors, and that the antagonism between the two drugs is of a competitive nature.
D000005:Abdomen; D000085:Acetates; D019342:Acetic Acid; D000818:Animals; D007700:Kinetics; D008297:Male; D051379:Mice; D009120:Muscle Cramp / Q000139:chemically induced / Q000188:drug therapy; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D013843:Thiazines / Q000037:antagonists & inhibitors*; D014991:Xylazine / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D015016:Yohimbine / Q000378:metabolism / Q000494:pharmacology*
D000085:Acetates; D011942:Receptors, Adrenergic, alpha; D013843:Thiazines; D014991:Xylazine; D015016:Yohimbine; D019342:Acetic Acid